Lataa...
Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy
Psoriasis is a chronic inflammatory disorder that is clinically characterized by scaly cutaneous plaques. New evidence suggests that dysregulation of interleukin (IL)-23, a key cytokine in the T-helper-17 pathway, plays a vital role in the development of psoriatic systemic inflammation. The novel bi...
Tallennettuna:
| Julkaisussa: | Ther Adv Chronic Dis |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
SAGE Publications
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6691657/ https://ncbi.nlm.nih.gov/pubmed/31448070 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040622319865658 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|